GlassScriptPhysician profile
Juan C Vila
NPI 1932196151
$6,004.27
in general payments reported to CMS, 2019-2025
19 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,671 · 2020: $370 · 2021: $849 · 2022: $962 · 2023: $954 · 2024: $718 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,152.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,950.07 | 2019-2024 | Micra, Symplicity G3, Reveal Linq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,100.45 | 2019-2025 | Jardiance |
| Pbg Puerto Rico LLC | $1,016.03 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $369.98 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $304.17 | 2019-2025 | Lokelma, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $284.00 | 2019-2025 | Eliquis |
| Boston Scientific Corporation | $185.56 | 2023-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $122.39 | 2019-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $121.90 | 2023 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $121.13 | 2025 | |
| Novartis Pharmaceuticals Corporation | $89.39 | 2019-2024 | |
| Medtronic Vascular, INC. | $88.76 | 2019 | |
| Gilead Sciences, INC. | $73.50 | 2019 | |
| Abbott Laboratories | $58.94 | 2019 | |
| Merck Sharp & Dohme LLC | $45.77 | 2024 | Verquvo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Puerto Rico INC. | $19.63 | 2025 | Kerendia |
| Pfizer INC. | $18.75 | 2019-2022 | |
| Amgen INC. | $17.00 | 2019 | |
| Pfizer Pharmaceuticals LLC | $16.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Vila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.